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enzymeAbstract Inclusion of metabolic considerations in the drug design process leads to signiﬁcant
development in the ﬁeld of chemical drug targeting and the design of safer drugs during past few
years which is a part of an approach now designated as Retro metabolic drug design (RMDD). This
approach represents systematic methodologies that integrate structure–activity and structure–
metabolism relationships and are aimed to design safe, locally active compounds with an improved
therapeutic index. It embraces two distinct methods, chemical delivery systems and a soft drug
approach. Present review recapitulates an impression of RMDD giving reﬂections on the chemical
delivery system and the soft drug approach and provides a variety of examples to embody its con-
cepts. Successful application of such design principles has already been applied to a number of mar-
keted drugs like esmolol; loteprednol etc., and many other candidates like beta blockers, ACE
inhibitors, alkylating agents, antimicrobials etc., are also under investigation.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.Contents
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Chemotherapeutic research started with the identiﬁcation of
lead structures. These lead structures are unique for each tar-
get. Lead structures often need to be developed by incorporat-
ing desirable safety, efﬁcacy and ADME characteristics
required for a ‘‘drug’’. For example- development of cimeti-
dine (drug) and ranitidine (drug) was from brimmed drug can-
didate and N-a guanyl histamine (drug candidate), that were
both developed from histamine (lead) (Ganellin, 1982; Brad-
shaw, 1993). Thus, we can say that in drug discovery we are
concerned to select a suitable drug candidate with promising
pharmacological activity for the development process. The
main aim of the drug design process is to bring down the tox-
icity level of a drug candidate with improved activity as well as
therapeutic index (Drews, 2000). But unfortunately, as the
pharmacological activity of a drug increases, the toxic effects
also increase and the therapeutic index remains unchanged.
To improve the therapeutic index one has to separate activity
and toxicity properties of a drug compound. The toxic or un-
wanted side effects are produced during the drug design pro-
cess because new structural moieties are introduced into the
drug candidate to enhance its activity and hence, the toxic or
unwanted pharmacokinetic properties will further be enhanced
during the drug design process. The high activity of a drug
candidate is of no use if it has high toxicity as well and the only
reason for the low success of a drug design process is the lack
of toxicity consideration during such a process. One way to de-
crease the drug toxicity is to design metabolically stable drugs.Figure 1 General metabolic pathway of drug and Retrometa-
bolic drug design strategy via soft drug approach and chemical
delivery system where D1, D2, D3 . . . are metabolites with similar
structure and activity of the parent A1, A2, A3. . . are metabolites
with dissimilar structure and activity of the parent compound, P1,
P2, P3 . . . are metabolites with different pharmacokinetic proﬁles,
I1, I2, I3 . . . are inactive metabolites and R1, R2, R3 . . . are
metabolites which are potentially reactive intermediates.At one glance, the idea looks very facilitating as one can avoid
unwanted toxicity by avoiding the metabolism of the drug and
a simpler pharmacokinetic route can be followed by a drug
controlled by only renal excretion. These non-metabolic drugs
are called as ‘hard drugs’ (Ariens and Simonis, 1977). But, the
idea of designing ideal hard drugs is not achieved till date be-
cause living organisms have developed mechanisms to metab-
olize the endogenous substances as well as for the
detoxiﬁcation (Gillette, 1979; Mannering, 1981). Most meta-
bolic processes aim at the transformation of foreign chemicals
into more easily eliminated hydrophobic conjugates (Picot and
Macherey, 1996).Thus, it is not enough for a molecule to just
have good pharmacodynamic property but pharmacokinetic
parameters also play a vital role for a molecule to become a
drug because the in vivo administration of a drug becomes a
troublesome process as it has to cross a number of biological
barriers (Bodor, 1977). The pharmacokinetic factors which af-
fect the in vivo administration of the drug are: absorption, dis-
tribution, metabolism and excretion (ADME). Thus, the basis
of successful drug discovery is the incorporation of the ADME
approach to the process. Out of four pharmacokinetic factors,
metabolic studies play an important role in drug discovery be-
cause the study of metabolic clearance pathways as the major
drug clearance pathway is very important in determining the
drugability of the molecule (Bodor, 1984). In early drug dis-
covery processes, the main role of drug metabolism is to pro-
vide a basis for choosing the chemical structures and lead
compounds with desirable drug metabolism and pharmacoki-
netic properties but nowadays metabolic studies are mainlyFigure 2 Concept of retrometabolic drug design.
292 Y.R. Bhardwaj et al.concerned to have a good safety proﬁle of the drug (Bodor and
Buchwald, 2000). Thus, it is necessary to take into consider-
ation the metabolic as well as the toxicity proﬁle of a molecule
during the drug design process. The metabolism of a foreign
compound by a given enzyme in the body can result in the for-
mation of either toxic or non-toxic metabolites. The metabolic
conversion of a drug can generate (as shown in Fig. 1):
1. Metabolites with similar structure and activity of the parent
drug (D1, D2, D3 . . .).
2. Metabolites with dissimilar structure and activity of the
parent compound (A1, A2, A3 . . .)
3. Metabolites with different pharmacokinetic proﬁles (P1, P2,
P3 . . .).
4. Inactive metabolites (I1, I2, I3 . . .).
5. Metabolites which are potentially reactive intermediates
(R1, R2, R3 . . .).
Therefore, xenobiotics do not always get converted into ac-
tive or inactive species but also into highly reactive intermedi-
ates like epoxides and radicals from non toxic compounds
which are responsible for tissue damage. Intrinsic toxicity of
a drug candidate which is a combination of biological mecha-
nism based inputs, non-speciﬁc chemical based inputs, inputs
based on other biological mechanisms like action is mediated
by some enzyme system or receptor system (Bodor and Buch-
wald, 2003).
2. Retrometabolic drug design principle
Inclusion of metabolic considerations in the drug design pro-
cess leads to signiﬁcant development in the ﬁeld of chemical
drug targeting and the design of safer drugs during the past
few years which is a part of an approach now designated as
Retro metabolic drug design (RMDD) (Bodor and Buchwald,
1997). The word ‘Retrometabolic’ means situated backward or
behind in position. These drug design strategies are designated
as retrometabolic because in these approaches metabolic path-CH3
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Figure 3 Progestin chemways are designed going backward as compared to actual met-
abolic processes. Retrometabolic drug design approach
signiﬁes a systematic methodology that combines structure
activity and structure metabolism relationships to develop lo-
cally active compounds with a safe and enhanced therapeutic
index.
Retrometabolic drug design concept involves two ap-
proaches so as to improve the therapeutic index of drug candi-
dates, chemical delivery system (CDS) and soft drug (SD)
approach as shown in Fig. 2. Chemical delivery system is de-
ﬁned as one in which a biologically inert molecule is converted
into an active drug by a number of steps enhancing the drug
delivery at a particular organ or site (Bodor and Kaminski,
1987). Soft drugs are the active isosteric or isoelectronic ana-
logs of a lead compound, a structure speciﬁcally designed to
allow a predictable metabolic route after exerting the desired
therapeutic effect (Bodor, 1982). The drug targeting by CDS
as well as SD approach requires the enzymatic system but
the principles of CDS and SD are altogether different. On
one hand, CDS is inactive and requires a number of steps to
get converted into the active drug, SDs are active by nature
and are deactivated by a predictable and controllable meta-
bolic route via a single detoxiﬁcation step. For a CDS, the
drug is present at the site due to enzymatic reaction and is ab-
sent in the rest of the body while in the case of SDs, the drug is
present at the site and absent in the other sites of the body be-
cause of enzymatic reactions at those sites of the body (Bodor,
1994, 1995).
2.1. Chemical delivery system (CDS)
Chemical delivery system is designed by recognizing speciﬁc
enzymes exclusively at the site of action. The concept of CDSs
has already been applied in a variety of drug targeting strate-
gies, achieving successful delivery to the brain, eye and other
organs of the body (Bodor et al., 1981; Bodor, 1985a, 1987,
1990, 1999; Bodor and Brewester, 1991; Bodor and Buchwald,
1998). The drug targeting through the CDS approach includesCH3
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Figure 4 Ketoxime analogs of b-adrenergic blockers.
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Figure 5 Dihydropyridine-pyridinium salt redox carrier-based
chemical delivery system for benzylpenicillins.
CH3
N
NH2
O
N3
OH
O
AZT (6a)
N
NH
O
N3
O
O
CH3
CH2
O
N+
CH3
N
NH
O
N3
O
O
CH3
CH2
O
N
CH3
AZT - Q+ 6(b) AZT - CDS (6c)
oxidation product
Figure 6 AZT-CDS.
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active drug. The system should have a covalent link between
the drug and carrier and one bond needs to be broken. The
CDS concept was evolved from the prodrug concept (Albert,
1958; Stella, 1975) but both the concepts are essentially differ-
ent. Prodrugs contain one or more moieties which protect or
enhance the overall delivery of the drug, but they lack target-
ing (Balant and Doelker, 1995). In a chemical delivery system,
the drug is converted into the inactive form by two moieties,
one is a target which is responsible for site speciﬁcity and tar-
geting, the other is the modiﬁer function, can be more than one
in number, for the protection of certain functional groups and
to prevent the drug from unwanted metabolic reactions (Bod-
or, 1985b).
A number of CDS have been designed to have successful
delivery of the medicaments to some organs.
Progestin chemical delivery system, 3a–c was developed to
transport gonadal steroids like estradiol and testosterone to
the CNS to avoid its peripheral untoward actions like hyper-
tension and weight gain (Fig. 3) (Brewester et al., 1986).
Due to poor ocular bioavailability of the drug following sys-
temic administration, the preferred route to treat most of the
ocular problems is the topical administration of the drug attrib-uted to hindrance by Blood retinal barrier (BRB), which is as
effective as the Blood brain barrier (BBB). The local adminis-
tration of drug to the eye too suffers with the problem of bio-
availability owing to some precorneal factors like tear
turnover, physicochemical mismatch with cornea and drainage
of the drug from the eye. So, in an effort to enhance the bio-
availability of the drug to the eye through systemic circulation,
ketoxime analogs of b-adrenergic blockers, 4a & b were
developed as antiglaucoma agents with high lipid solubility
and reduced systemic toxicity than the oxime analogs (Bodor
et al., 1988a). A new site speciﬁc chemical delivery system 4c
for alprenolol was also designed (Fig. 4) (Bodor and Elkouss
1991).
Penicillins and cephalosporins are used widely to treat
many bacterial infections because of low toxicity and low min-
imum inhibitory concentration over other b-lactam antibiotics
but all have a problem related to their transportation across
BBB as well as showing a rapid elimination rate through body.
But benzylpenicillins are still the drug of choice not only to
treat bacterial meningitis but also other infections of the brain,
such as AIDS-related brain syphilis, brain abscesses, Lyme’s
disease etc. because of remarkable BBB penetration. A dihy-
dropyridine-pyridinium salt redox carrier-based chemical
delivery system for benzylpenicillins was developed (Fig. 5)
(Pop et al., 1991).
Zidovudin (AZT), 6a exerts signiﬁcant activity against
HIV. But, the restricted transport of this drug through BBB re-
sults in low drug concentration in the CNS and only marginal
retroviral activity of zidovudin is detected. The CDS, 6c of zid-
ovudin has been developed with improved CNS uptake of the
drug. The AZT-CDS was found to be three to ten times active
than AZT in the brain. Owing to this target based approach,
AZT-CDS was not only more effective in inhibiting the HIV
replication but it was also less toxic to the host lymphocytes
than AZT (Fig. 6) (Brewester et al., 1995).
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Figure 7 Enkaphlin analog CDS.
294 Y.R. Bhardwaj et al.A CDS has been developed for the targeted delivery of enk-
aphlin analog, 7a to the brain. In this design, a synthetic leu-
cine-enkaphlin analog, DADLE, 7b a well known opioid
agonist, is surrounded by functional groups that protect the
peptide from the action of peptide degrading enzymes and pro-
vide sufﬁcient lipophilicity for penetration through BBB
(Fig. 7) (Prokai et al., 1996).
The design, synthesis and pharmacological assessment of
the brain targeted chemical delivery system, 8a for a kyotro-
phin analog (Tyr-Lys) has also been developed. The spacer
used in this design can be proline, 8b, proline- proline, 8c or
proline- alanine, 8d (Fig. 8) (Chen et al., 1998).
Oxime, 9a or methoxime, 9b analogs have been designed as
potential antiglaucoma agents of known b-adrenergic blockers
(Fig. 9) (Bodor and Buchwald, 2005).
A novel carrier system for the sustained drug delivery to the
brain, 10a & b was synthesized as a group of 1-malonyl-1,4-
dihydropyridine derivatives. This CDS ensures a deﬁnite shelf
life, a good rate of oxidation, non-neurotoxic and easy excre-
tion from the brain (Fig. 10) (Hassan et al., 2009).
A new CDS of BZD was designed as the GABA agonist
with improved aqueous solubility. These analogs preserve the
potency as well as the agonist proﬁle (Fig. 11) (Jeffrey et al.,
2002).
Centrally acting TRH analogs are synthesized by solid
phase Zincke Reaction. The prodrugs of these analogs were
obtained by a reduction mechanism and after enzymatic oxida-
tion and sustained release, degradation resistant analogs were
found with enhanced bioavailability in the brain (Fig. 12)
(Katalin et al., 2002).A most recent CDS 13a–c was designed to increase the sta-
bility of 1,2-dihydropyridine derivatives toward oxidation and
hydration reactions (Fig. 13) (L´ena¨ıg et al., 2009).
2.2. Soft drug design
Soft drugs are the isosteric or isoelectronic analogs of a lead
compound that have a predictable and controllable metabolic
route so that the toxic effects of the drug could be overcome
with an improvement in the therapeutic index of the drug.
The desired activity of the soft drugs is generally local and they
are applied on or near the site of action. Thus, the soft drugs
produce their pharmacological effect locally, but their distribu-
tion away from the site of action results in metabolic deactiva-
tion, which avoids undesirable activity and toxicity. Bodor and
Kamenski ﬁrst introduced the Soft Drug concept in 1980 and
since then ﬁve major strategies of soft drug design have been
identiﬁed which are as follows-
1. Soft analogs
2. Soft drugs based on the inactive metabolite approach
3. Controlled release endogenous agents
4. Activated soft compounds
5. Active metabolite base soft drugs
3. Key strategies for soft drug design
3.1. Soft analogs
These classes of compounds are the structural analogs of the
known active drugs which have an in-built metabolically sensi-
tive moiety which is responsible for their one step controllable
detoxiﬁcation. The sensitive moiety is so designed that the
detoxiﬁcation is achieved soon after the drug has shown its de-
sired pharmacological activity, not allowing any other route of
metabolism to take place.
The soft analog design strategy involves some basic princi-
ples as listed below:-
1. New soft analogs are isosteric/isoelectronic with the lead
compound.
2. The inbuilt metabolically sensitive moiety is such that it
should not hinder the pharmacological activity of the drug.
3. The metabolically sensitive moiety is located within the
molecule in such a manner that the overall physical, phys-
iochemical, steric and complementary properties of the soft
analog are very close to the lead compound.
4. The inbuilt metabolically sensitive moiety is preferably the
only route of metabolism.
5. There is predictable metabolism that can be controlled by
structural modiﬁcations.
6. The resulting metabolic products are non toxic or with low
toxicity
7. There is no need of any enzymatic process leading to highly
active intermediates, the oxidative metabolism must be
replaced by the hydrolytic process.
The designed route of metabolism should produce struc-
tural change in the molecule, which is responsible for its com-
plete deactivation. Simple conjugation or simple one function
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296 Y.R. Bhardwaj et al.introduction into the molecule leads to complete deactivation
of the molecular structure.
The design of labile quaternary ammonium salts, 14a–c as
soft antimicrobials with improved pharmacokinetic properties
and less toxic effects was reported (Fig. 14) (Bodor et al.,
1980a).
Some soft quaternary ammonium L-carnitine esters, 15a &
b with broad spectrum antimicrobial activity were reported
(Fig. 15) (Calvani et al., 1998).N
CH3
NH
O
MeO
MeO
13a
N
CH3
OMeO
MeO
R=
1
Figure 13 Design oSoft analog approach was used in order to synthesize the
soft analog of propantheline against indomethacin-induced
gastric ulceration and in inducing mydriasis. The increased
metabolic lability with equipotency of these soft analogs is
an advantage over the propantheline which had many side ef-
fects like eczema, erythrema etc. (Fig. 16) (Brouillette et al.,
1996).
Some short acting antiarrhythmic agents, 17a–e were syn-
thesized as a replacement of the antiarrythmic drug lidocain
which had a problem of reduced systemic and central nervous
effects (Fig. 17) (Stout et al., 1989).
Some muscranic receptor antagonists, 18a & b were re-
ported as a class of anticholinergic agents which are soft
analogs of some known anticholinergics with local but
practically no systemic activity to show antispasmodic, anti-
secretary and mydriatic effects. These compounds particu-
larly act as inhibitors of eccrine sweating (Fig. 18) (Bodor
et al., 1980b).N
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This is one of the most useful and successful strategies for
designing safe and selective soft analogs. It also involves the
metabolism of active species. This approach deals with the
structural modiﬁcations in the inactive, excreted metabolite
of an active drug in order to allow the metabolic reconversions
to occur in a facile, one step and controllable manner, with a
return to the very inactive metabolite from which the design
began.
The strategies to be applied for inactive metabolite based
soft drug approach are:-NH2
R
+
Cl
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OAc
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R
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R
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N
H
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R
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N
N
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Figure 17 Short acting1. The design starts with the inactive, excreted metabolite of
the active drug.
2. The speciﬁc chemical modiﬁcations of the inactive metabo-
lite which makes its structure isosteric or isoelectronic to
the active metabolite of the drug or the active drug itself.
3. New structure is such that there is a one step conversion
into the inactive metabolite without any metabolic
conversions.
4. By structural modiﬁcations we can control the metabolic
routes as well as speciﬁc binding and transport properties
of the new soft compounds.
Anticholinergics are the muscranic receptor antagonists
which inhibit the effects of acetylcholine by blocking its bind-
ing to the muscranic receptors present at neuroeffector sites on
smooth muscles, cardiac muscles and gland cells in peripheral
ganglia and in CNS. These anticholinergics are used in the
treatment of asthma, prevention of motion sickness, mydriasis,
Alzheimer’s disease, Parkinson’s disease and disorders ofO
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298 Y.R. Bhardwaj et al.intestinal motility, cardiac function and urinary bladder func-
tioning. Soft anticholinergics, 19a & b were designed using an
inactive metabolite based soft drug approach (Fig. 19)
(Buchwald and Bodor, 2006).The design of analogs of highly potent synthetic steroids,
20a & b with expected hydrolytic stability has been reported
to ensure the topical administration of these compounds
(Fig. 20) (Little et al., 1999).
Focusing on shorter outpatient surgical procedures inactive
metabolite based approach was used to design opioid analge-
sics, 21a & b with prolongation of pharmacological effects
upon infusion (Fig. 21) (Feldman et al., 1991).
A number of ultra short acting antiarrhythmics has been
designed, 22a & b. Their advantage over long acting agents
is that they rapidly achieve the steady state plasma concentra-
tion and therapeutic effects because of short biological half life
(Fig. 22) (Baxter et al., 1992).
The design of b-adrenoreceptor antagonists, 23a & b de-
rived from metoprolol has been reported. This includes
OCH3
CH3
OH
O
O
CH2ClOO
O
C2H5
O
CH3
CH3
OH
O
O
CH2ClOO
O-
Loteprednol etabonate PJ 91
Figure 25 PJ 91.
R= Me,Et,MOM,CH2CH2F,MTM
CH3
OH
CH3
OR
O
CH3
OH
CH3
OR
O
26 a 26 b
Figure 26 Cyclosporin A analogs.
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Figure 27 Thiazolidine type derivatives of progesterone.
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Figure 29 Soft N-Chloramines.
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with effective antiglaucomal activity (Fig. 23) (Erhardt et al.,
1982).
Another cardioselective series of ultra short acting b-block-
ers were previously reported with long duration of action by
using inactive metabolite based soft drug approach (Fig. 24)
(Bodor et al., 1988b).
The synthesis of loteprednol etabonate was described which
gets converted into PJ 91. The drug is locally acting and with
no systemic side effects. This drug was developed specially for
topical use but because of low oral availability, this drug can
also be used for pulmonary and ocular delivery (Fig. 25)
(Hochhaus et al., 1992).
A rapid and efﬁcient semi synthetic route to a family of
Cyclosporin A analogs, 26a & b were investigated exploiting
the oleﬁn metatheses reaction (Fig. 26) (Lazarova et al., 2003).O
O ClCH3
28 a 2
Figure 28 Soft alkyl3.3. Controlled released endogenous agents or natural soft drugs
Natural hormones and other biologically active agents such as
neurotransmitters can be considered as natural soft drugs since
our body has fast and efﬁcient routes of their metabolism and
their metabolism does not result in the production of toxic
metabolites, particularly if they are not present in concentra-
tions above the normal level. Thus, the design of soft drugs
from these endogenous agents can be done by adopting the
prodrug-soft drug combination also called as the pro-soft drug
approach. This will provide a sequence of-Inactive delivery-
protective form-active soft drug-inactive metabolites via non
toxic intermediates.
Progesterone and testosterone are natural soft drugs but
they have a problem related to their metabolism. They metab-
olize very quickly. This problem can be overcome by develop-
ing a delivery system for these drugs by the design of
thiazolidine type derivatives of progesterone and testosterone
(Fig. 27) (Bodor and Sloan, 1982).
3.4. Activated soft compounds
These compounds do not include the analogs of known drugs.
The process involves starting with a known non toxic com-
pound in which the pharmacologically active moiety is intro-
duced which is responsible for its pharmacological activity.O
O Cl
O
O Cl
28 c
8 b
ating compounds.
O
CH(OH)CH2NHC(CH3)3
CH3
O
CH(OH)CH2NHC(CH3)3
OH CH3
O
CH(OH)CH2NHC(CH3)3
O CH3
O
CH(OH)CH2NHC(CH3)3
O
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O
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Bufuralol Active metabolite
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Figure 30 Active metabolite based soft drugs.
300 Y.R. Bhardwaj et al.The activated form is then changed to the non active, non toxic
starting molecule after performing its therapeutic role by a one
step detoxiﬁcation reaction
Some soft alkylating compounds, 28a–c as active, site spe-
ciﬁc/site selective potential antitumor agents were reported.
These agents are characterized by a predictive in vivo meta-
bolic destruction to non-toxic metabolites after the achieve-
ment of the therapeutic role (Fig. 28) (Bodor and Kaminski,
1980).
A number of soft N-chloramines, 29a & b containing nitro-
gen-chlorine bonds of different polarity have also been synthe-
sized (Fig. 29) (Kaminski et al., 1976).
3.5. Active metabolite based soft drugs
It is well known that most drugs undergo stepwise metabolic
degradation via oxidative metabolic routes to yield structural
analogs having similar activity like that of the parent drug.
These metabolic routes not only put a burden on the body’s
oxidative enzyme system but also produce a number of thera-
peutically active compounds with different selectivity, binding,
distribution and elimination properties. But the development
of safe and active general dosing of these compounds is prac-
tically impossible because of a variety of combinations of ac-
tive species in different individuals depending upon their
enzyme system as well as the presence of other compounds
requiring same enzymes.
As this class refers to the metabolic products of a drug that
retains signiﬁcant activity as that of the parent drug, the judi-
cious selection of an active metabolite can yield a potent drug
that will undergo one step deactivation and thus detoxiﬁca-
tion. The one step deactivation is because the active metabolite
is already in highest oxidation state. In other words we can say,
the drug of choice should be the active metabolite which is in
the highest oxidation state (Fig. 30) (Hwang et al., 2000).4. Conclusion
For a drug design process it is not only important to increase
the activity but also to reduce the side effects. Retrometabolic
drug design principle aims to design new, safe drugs with an
improved therapeutic index and lesser side effects by integrat-
ing structure activity and structure metabolic relationships.
Soft drug design and Chemical delivery system are the two ap-
proaches of retrometabolic drug design. Both approaches rely
on a known active lead and they both can result in an approv-
able drug product than other strategies of drug design.Acknowledgement
The authors are grateful to Prof. Aditya Shastri, H’norable
V.C., Banasthali University, Rajasthan.
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